We determined the incidence of severe bleeding from gastric antral vascular ectasia (GAVE) after myeloablative hematopoietic cell transplant and the outcomes after treatment with endoscopic neodymium:YAG laser photocoagulation. From 1992 to 2005, the incidence of severe bleeding from GAVE was 6/4491 (0.13%). All patients had received oral busulfan and four had sinusoidal obstruction syndrome. Gastrointestinal bleeding began a median of 53 days after transplant (range 15-2952). After GAVE was diagnosed by endoscopic and histologic findings, a median of three (range 2-7) sessions of laser therapy were required to control the bleeding with a median of 2737 J (range 1117-6160 J) per session. A median of 16 units (range 4-44) had been transfused prior to laser therapy and a median of four additional units (range 0-113) were transfused until bleeding was controlled. All patients were followed for at least 70 days after the last laser therapy session, with no further episodes of bleeding. Complications were mild and included abdominal pain and asymptomatic ulceration; however, one patient required gastrectomy due to gastric necrosis following transarterial embolizations. In summary, severe bleeding from GAVE is rare following hematopoietic cell transplant. Treatment with endoscopic therapy using the Nd:YAG laser is safe and effective.
Introduction
Gastrointestinal bleeding is very common following hematopoietic stem cell transplantation, but in most cases, bleeding is related to thrombocytopenia and ceases with restoration of platelet counts. 1 The incidence of persistent, high-volume bleeding after transplant is 2.4% with a case fatality rate of 40%. 2 The most frequent cause of severe intestinal bleeding is refractory graft-versus-host disease (GVHD), a condition that is usually fatal. 2 A less common but treatable cause of severe bleeding is gastric antral vascular ectasia (GAVE), which appears to be caused by the transplant procedure itself, specifically the use of oral busulfan and the development of portal hypertension. 3, 4 GAVE in the setting of hematopoietic cell transplant differs from the more common presentation which is often seen in patients who are elderly, have chronic liver disease, or have connective tissue disease. [5] [6] [7] GAVE in the post transplant setting is almost always a diffuse process involving the entire antrum, often with extension into the body of the stomach, while GAVE in the nontransplant population usually presents as a typical 'watermelon stomach,' with the classic endoscopic findings of linear erythematous stripes within the antrum which radiate out from the pylorus (Figure 1 ). 3 We report the incidence of severe bleeding from GAVE after myeloablative hematopoietic cell transplant and the results of endoscopic therapy with the neodymium:YAG (Nd:YAG) laser in these patients.
Materials and methods

Patient selection
Patients undergoing myeloablative hematopoietic cell transplant between 1992 and 2005 (N ¼ 4491) were followed closely at the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance until they returned to the care of referring physicians, usually at day þ 80 post transplant. All patients who developed gastrointestinal complications were evaluated by one of us (GBM, DMH, GS, or MBK). We do not routinely endoscope patients who do not have signs or symptoms of gastrointestinal problems and cannot estimate the incidence of GAVE, but rather the cases reported here represent all patients who had persistent bleeding from GAVE during this period. Their medical records were reviewed under a protocol approved by the Institutional Review Office of the Fred Hutchinson Cancer Research Center.
Technique of hematopoietic cell transplantation
The methods of transplantation during the years of this study have been previously reported. Myeloablative conditioning therapy was given primarily in the form of cyclophosphamide-based regimens (cyclophosphamide plus total body irradiation or oral busulfan plus cyclophosphamide), busulfan/melphalan/thioTEPA, or high-dose melphalan. 8, 9 All patients received prophylactic medications, usually fluconazole, acyclovir, and cyclosporine or tacrolimus plus methotrexate as prophylaxis against GVHD. The day of infusion of stem cells is day zero, and all subsequent events are timed relative to this date.
Endoscopic hemostasis using the Nd:YAG laser All patients underwent upper endoscopy in a standard fashion using either an Olympus or a Pentax video gastroscope. For application of laser therapy, an OptiLITE 600 micron fiber assembly with flexible cooling sheath (EZ2060F, manufactured by Xintec Corporation, Oakland, CA, USA) was advanced through the working channel of the endoscope. The Nd:YAG infrared beam was generated with a KTP/Nd:YAG Surgical Laser System (Model 814, manufactured by Laserscope, San Jose, CA, USA). As the emission is invisible, a helium-neon aiming beam is used in conjunction with the Nd:YAG to visualize the focal target area. Using a power setting of 50 W, the actively bleeding mucosa was treated with the laser beam applied with a painting technique, where the aiming beam is used to 'paint' the mucosa in a side-to-side or radial fashion, usually starting from the pylorus. The frequency and number of laser endoscopy sessions was based on the frequency of blood transfusions and the clinical signs and symptoms of gastrointestinal hemorrhage.
Results
Patient demographics
Seven patients developed persistent gastrointestinal bleeding caused by GAVE between 1992 and 2005. Six of these patients had been transplanted at our medical center during this period, giving an incidence of 0.13%. Case 3 had been transplanted elsewhere and is not part of the calculation of the incidence of GAVE. The demographics of the seven patients are given in Table 1 . Two of the patients, Cases 1 and 2, have previously been reported. 3 Description of patients with GAVE Case 1. This 17-year-old man developed coffee ground emesis and melena on day þ 94. His post transplant course had been complicated by oral mucositis, sinusoidal obstruction syndrome, hemorrhagic cystitis, and acute GVHD of the skin. Endoscopy on day þ 96 revealed diffuse antral oozing of blood without an underlying erosion or ulcer. Antral biopsy specimens showed GAVE and no evidence of either GVHD or infection. Despite platelet counts of greater than 50 000/mm 3 , the patient's bleeding continued unabated, requiring transfusion of 14 units of red blood cells. On day þ 99 endoscopy revealed continued antral oozing and erythema of the duodenal Case 2. This 52-year-old man developed maroon stools at day þ 69. His post transplant course had been complicated by mild sinusoidal obstruction syndrome, acute GVHD, a urinary tract infection, hydronephrosis, and hemorrhagic cystitis. GVHD had been proven at endoscopy on day þ 43. In addition to histologic changes of GVHD, 10 GAVE was present as an incidental finding. After day þ 69, when his intestinal bleeding began, 7 units of packed red blood cells were transfused over the ensuing 3 weeks. Endoscopy on day þ 92 revealed fresh blood clots in the antrum. Upon washing away the clots, a slow oozing of blood was noted from multiple linear red stripes, consistent with GAVE. No biopsy specimens were taken because of thrombocytopenia. On day þ 94, endoscopic Nd:YAG laser photocoagulation (5490 J) was applied to the red stripes. Following this therapy the patient required less frequent but continued red cell transfusions. Endoscopy on day þ 100 showed multiple antral ulcerations with overlying eschar at previous laser therapy sites. Continued oozing from areas of untreated striped mucosa was subsequently treated with laser therapy (1180 J). The patient's transfusion requirements continued to decline. A third laser treatment (2380 J) was performed on day þ 121 with cessation of bleeding. Endoscopy on day þ 155 showed a normal antrum. He did not require further transfusion or endoscopic therapy during 9 months of follow-up.
Case 3. This 47-year-old woman developed intermittent melena and anemia 8 years after her autologous transplant. Her bleeding initially appeared in the perioperative period for a hip replacement, requiring 22 units of packed red cells. Endoscopy revealed scattered vascular ectasias in the antrum that were treated at another medical facility with argon plasma coagulation (APC). However, because she continued to bleed, she was referred to our medical facility. Endoscopy 70 days after the onset of bleeding revealed four small ulcers, likely due to previous APC therapy, and multifocal angioectasias throughout the antrum, some with active bleeding. She was treated with endoscopic Nd:YAG laser photocoagulation (1768 J) to the antrum. Her melenic stools subsequently stopped, and her transfusion requirement declined. She received three additional sessions of laser therapy (1117, 3886, and 2291 J) over the next 3 months with cessation of her bleeding and no further transfusion requirements over 4 months of follow-up.
Case 4. This 55-year-old woman developed nausea, vomiting, and melena on day þ 33. Her post transplant course had been complicated by oral mucositis, GVHD, sinusoidal obstruction syndrome, and a right pleural effusion. Despite correction of her thrombocytopenia and coagulopathy, she continued to bleed. Endoscopy on day þ 48 revealed a large clot in the prepyloric region with some active oozing. As the clot was unable to be mobilized away from the mucosa, the mucosa around the clot was injected with epinephrine, with apparent slowing of the bleeding. Owing to ongoing blood loss, repeat endoscopy 1 week later showed similar adherent clots and mild active oozing, but no underlying erosion or ulceration. Biopsies showed GAVE with histologic evidence of transepithelial bleeding from dilated capillaries. As a result of continued melena, on day þ 61 endoscopic Nd:YAG laser photocoagulation (2600 J) was applied to the antrum. Her melena and transfusion requirement diminished, then ceased, following two additional sessions of laser therapy (1172 and 3972 J). She was without further bleeding during 2 years of follow-up.
Case 5. This 48-year-old man developed epistaxis and melena on day þ 15. His post transplant course had been complicated by oral mucositis. Despite multiple platelet transfusions, his melena persisted. Endoscopy on day þ 18 revealed a large clot and diffuse oozing in the antrum without erosion or ulceration. Biopsy specimens from the antrum revealed GAVE without evidence of either GVHD or infection. On day þ 21 endoscopic Nd:YAG laser photocoagulation (5510 J) was applied to the antrum. His bleeding stopped for two days, but was followed by recurrent hematemesis and melena. Endoscopy revealed ulcers at the site of previous laser therapy, diffuse antral oozing, and a large clot in his stomach. Biopsies again revealed no evidence of infection or GVHD. His bleeding continued, and other interventions were tried without success, including intravenous infusions of aminocaproic acid and octreotide, repeat endoscopic epinephrine injection, bipolar cautery, and embolization of the left gastric artery. On day þ 34, endoscopic Nd:YAG laser photocoagulation (3700 J) was applied to bleeding areas in the antrum, but he still continued to bleed. At repeat angiography on day þ 40 active extravasation of contrast from the left gastric artery was visualized, so this vessel was embolized a second time. Despite this intervention, bleeding continued. Five additional sessions of endoscopic Nd:YAG laser photocoagulation were applied (5208, 6160, 5867, 2296, and 3083 J) during days þ 42-62 with a subsequent decline in his transfusion requirement. He then developed abdominal pain on day þ 68 caused by splenic infarction and necrosis of the gastric wall. A total gastrectomy with a Roux-en-Y esophagojejunostomy was performed on day þ 70. At surgery, findings included a contained perforation of the lesser curve of the stomach in the vascular distribution of his two previous embolizations, a completely occluded left gastric artery, and a large amount of old clot and purulent material in the stomach. Following this operation, the patient had no further evidence of bleeding. However, he died on day þ 284 from multiorgan failure with Escherichia coli sepsis and adult respiratory distress syndrome.
Case 6. This 57-year-old woman developed nausea, vomiting, Hemoccult-positive stools, and a decline in her hematocrit at day þ 37. Her post transplant course had been complicated by oral mucositis and gastric GVHD.
Endoscopy on day þ 40 revealed some streaks of old blood in the body of the stomach, several linear areas of edema and erythema with hemorrhagic spots in the antrum, and histology showing GAVE. Over the next week she continued to bleed, and on day þ 49 she was treated with endoscopic Nd:YAG laser photocoagulation (4595 J) to the antrum. Her melena subsequently ceased and no further red cell transfusions were required. She had a second session of laser photocoagulation (1369 J) on day þ 55. She had no further evidence of bleeding over 2 months of follow-up.
Case 7. This 38-year-old woman developed nausea, vomiting and worsening anorexia suggestive of GVHD at day þ 31. Her post transplant course had been complicated by oral mucositis, acalculus cholecystitis, a urinary tract infection, severe sinusoidal obstruction syndrome, and acute renal failure requiring hemodialysis. At endoscopy on day þ 32, diffuse areas of erythema and edema in the antrum were seen, along with linear punctate lesions at sites of recent bleeding. Biopsies demonstrated both GVHD and GAVE. On day þ 53, she developed progressive abdominal pain, hemetemesis, hematochezia, melena, and a drop in her hematocrit. Endoscopy on day þ 58 revealed diffuse hemorrhage from antral mucosa, without erosion or ulceration, consistent with GAVE. On day þ 60, she underwent treatment with endoscopic Nd:YAG laser photocoagulation (3280 J) to the antrum, with a decreased rate of bleeding. She received two additional sessions of laser therapy (2431 and 2697 J) with no further clinical evidence of bleeding over 3 months of follow-up.
Discussion
We report here a consecutive series of patients with severe gastrointestinal bleeding from GAVE following hematopoietic cell transplant who were treated with endoscopic Nd:YAG laser photocoagulation therapy. The major findings in this case series are as follows: (1) bleeding from GAVE continues to be a problem for patients undergoing hematopoietic cell transplants following myeloablative conditioning regimens, albeit at a frequency of o1%; (2) recognition of GAVE as the cause of ongoing bleeding remains problematic, as clots and fresh blood often obscure the field of vision and the lesions of GAVE are usually diffuse, rather than arrayed as red stripes; (3) the use of oral busulfan as a component of the conditioning regimen was common to all the cases of serious bleeding caused by GAVE; and (4) endoscopic hemostasis using the Nd:YAG laser is effective treatment for bleeding caused by GAVE.
GAVE is a well known, albeit uncommon, cause of bleeding following hematopoietic transplant, first reported by Marmaduke et al. 11 in 1994. In that series, 36% of patients (10/28 patients) with gastric biopsies who had received bone marrow transplants following a conditioning regimen of busulfan, cyclophosphamide and total body irradiation had histologic evidence of GAVE. Of those patients with GAVE 80% (8/10 patients) had clinical evidence of gastrointestinal bleeding, compared to 22% of those without GAVE (4/18 patients). Even in that series, it was apparent that GAVE as a histologic diagnosis was much more common than GAVE as a cause of bleeding. This finding is further supported in our series, in which two patients (Cases 2 and 7) were discovered to have GAVE on gastric biopsies without antecedent signs or symptoms of gastrointestinal bleeding. These two patients later developed clinically significant bleeding, however. As we do not endoscope patients in the absence of symptoms, we cannot determine the incidence of GAVE in this population. Based on sporadic findings of incidental GAVE in gastric biopsies, patients with ongoing bleeding from GAVE may represent only a fraction of those with the histologic lesion. In 2003, Ohashi et al. 4 reported the use of metoprolol to successfully treat three patients with bleeding from GAVE following hematopoietic transplant, leading them to postulate that GAVE in this setting may be associated with portal hypertension. Since portal hypertension after transplant is usually transient, beta blocker use in this population may be effective, even though it is not usually beneficial in reducing bleeding from GAVE in patients with cirrhosis of the liver.
The identification of GAVE as the source of bleeding in patients who have received hematopoietic cell transplants can be difficult. These patients often present with diffuse antral bleeding and not with the classic red stripes, as seen in Figure 1b . When clots or fresh blood is present, it is difficult to exclude an underlying lesion, such as an ulcer, as a cause of bleeding. This issue is further compounded by the high prevalence of thrombocytopenia in this population, which clearly can both precipitate and worsen bleeding, especially when compared to the nontransplant population with GAVE, in whom bleeding is usually occult. Additionally, in the setting of active gastrointestinal hemorrhage, especially when combined with thrombocytopenia, many endoscopists are hesitant to biopsy a bleeding lesion for fear of exacerbating the problem. However, our experience has shown us that histologic and virologic studies may be the only reliable way to detect GAVE and to exclude viral infections in this setting. 3, 11, 12 Oral busulfan appears to be necessary for the development of GAVE following hematopoietic cell transplant. Busulfan is given in tablet form, often contained within a gelatin capsule, and its retention in the antrum and mucosal absorption may be the proximate cause of GAVE. 4, 11 Oral busulfan is formulated as 2 mg tablets within gelatin capsules, resulting in the ingestion of over 500 such tablets over a 4-day period to achieve a dose of 16 mg/kg in an adult. With the advent of intravenous forms of busulfan, it will be interesting to see whether the incidence of GAVE and of bleeding from GAVE declines, perhaps due to the elimination of the direct toxic effects of busulfan on the gastric mucosa following ingestion. 4, 11 There also appears to be a higher incidence of portal hypertension caused by sinusoidal obstruction syndrome in this population, which has also been noted by Ohashi et al. 4 As our candidates for transplant are carefully screened for the presence of chronic liver disease, it is unlikely that underlying cirrhosis was responsible for GAVE lesions, but rather portal hypertension developed as a result of sinusoidal liver injury from the myeloablative conditioning regimens. It is not difficult to postulate that increased portal venous pressures may play a role in increasing the risk of bleeding from GAVE in these patients, as GAVE is histologically identical to portal hypertensive gastropathy, a cause of bleeding in patients with cirrhosis. Whether there is a threshold value of portal pressure that increases the risk of bleeding from GAVE is an open question; we do not have data on wedged hepatic venous pressure gradients in these patients that allows us to address this issue.
Several authors have found Nd:YAG laser therapy to be effective for the treatment of GAVE associated with other medical conditions, such as cirrhosis, connective tissue disease, valvular heart disease, and chronic renal failure. 5, [13] [14] [15] [16] [17] In this series, we report six patients who were successfully treated, as evidenced by a decline in the number of packed red blood cells transfused, stabilization of the hematocrit, and lack of clinical signs of gastrointestinal bleeding, even when other therapies directed at GAVE failed to stop the bleeding. One patient required a gastrectomy because of ischemic gastric necrosis from angiographic transarterial embolization.
In general, laser therapy was well tolerated. Complications included transient abdominal pain and asymptomatic gastric ulceration and eschar formation. In those patients with ongoing bleeding who require repeat endoscopy, it can be difficult to determine whether the bleeding is from the laser-induced mucosal injury or ulceration or from the untreated areas of GAVE. As mentioned above, one patient did suffer a contained perforation, but given his two prior left gastric artery embolizations, the presence of gastric necrosis, and the location of the perforation, it is likely that his prior arterial embolizations were causal. However, since there is a previous report of gastric perforation from laser therapy, 16 which occurred primarily with the authors' initial use of the laser and was thought to be due to an excessively high-power setting, we are not able to definitively determine whether the laser therapy also contributed to this adverse outcome.
Several other endoscopic thermal treatments have been used in patients with GAVE, including multipolar probes, heater probes, and APC. 18 The multipolar and heater probes require tissue contact and can thus induce bleeding and treating large surface areas can be difficult and time consuming. APC is accomplished without tissue contact but the probe must be placed within a few millimeters of the mucosal surface. Although we have not compared the two treatment modalities directly, we have preferred to use Nd:YAG laser therapy rather than APC in controlling hemorrhage from GAVE following hematopoietic cell transplantation for several reasons. First, active bleeding may absorb all of the fulgurating energy from the APC, leaving none to coagulate the underlying abnormal blood vessels. The higher power, more deeply penetrating laser can simultaneously coagulate the active bleeding and ablate the underlying vessels. In addition, endoscopic delivery of the laser beam to large areas of tissue is possible because the laser catheter does not have to be closely approximated to the mucosa, as does the APC catheter. Therefore, in our view, Nd:YAG therapy is preferred for treatment of diffuse hemorrhage from GAVE with an overlying layer of blood or clots because of the greater depth of penetration of energy to the underlying mucosa.
